KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications

(2010) Antoine Italiano et al.   ANNALS OF SURGICAL ONCOLOGY

Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

(2010) S. E. Baldus et al.   CLINICAL CANCER RESEARCH

Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review

(2010) Jolien Tol et al.   CLINICAL THERAPEUTICS

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

(2010) Wendy De Roock et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer

(2009) K. -L. Garm Spindler et al.   ANNALS OF ONCOLOGY

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant

(2009) F Molinari et al.   BRITISH JOURNAL OF CANCER

EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases

(2009) K. Schmid et al.   CLINICAL CANCER RESEARCH

High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue

(2009) Jolien Tol et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

(2009) Fotios Loupakis et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis

(2009) Paloma Cejas et al.   PLoS One

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

(2008) F. Perrone et al.   ANNALS OF ONCOLOGY

K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy

(2008) M.-C. Etienne-Grimaldi et al.   CLINICAL CANCER RESEARCH

Mutations ofKRASandBRAFin Primary and Matched Metastatic Sites of Colorectal Cancer

(2008) Salvatore Artale et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

(2008) D. Santini et al.   ONCOLOGIST